A Phase l/IIa, randomized, double blind, placebo-controlled, parallel group, pilot study to assess the safety and efficacy of a therapeutic HSV-2 DNA vaccine in HSV-2 positive adults

Trial Profile

A Phase l/IIa, randomized, double blind, placebo-controlled, parallel group, pilot study to assess the safety and efficacy of a therapeutic HSV-2 DNA vaccine in HSV-2 positive adults

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Herpes simplex virus DNA vaccine (Primary)
  • Indications Herpes simplex virus type 2 infections
  • Focus Adverse reactions
  • Sponsors Admedus
  • Most Recent Events

    • 19 Oct 2016 Interim results were published in the Admedus Media Release.
    • 04 Mar 2016 Interim results from the first 20 patients published in an Admedus media release.
    • 04 Mar 2016 Analysis of the unblinded data from the first 20 patients is expected in Q3 2016 and full trial analysis data is expected to be available by Q2 2017, according to an Admedus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top